Good news: By the end of the year, four more vaccines will reach the country, and there will be no shortage of vaccines

Good news: By the end of the year, four more vaccines will reach the country, and there will be no shortage of vaccines

India is fighting the second wave of Corona. Experts believe that the second wave will be at its peak until July and August. However, the peak will come at different times in different states, and at the same time, there is a possibility of a third wave. Experts believe that the third wave will wreak havoc on the country in November and December. Children will be most affected in the third wave. To avoid this, the clinical trial of the vaccine has also begun. Here, by the end of the year, it is expected that 4 more vaccines will be introduced into the country. There are several vaccines currently in the pipeline. According to media reports, half a dozen vaccines will be on the market. There are currently three vaccines available in the country, two of which are made in India, Covashield and Covaccine. At the same time, the Russian Sputnik vaccine is now also available. The Sputnik vaccine will be available in hospitals from the second week of June.

Covovax Vaccine

The Serum Institute of India (SII) based in Pune produces the Oxford AstraZeneca vaccine under the name “Covishield”, but also produces the protein-based COVID-19 vaccine NVX-CoV2373 under the name “CovoVax”. This vaccine was developed by the American biotechnology company Novovax. Production of Covovax from the Serum Institute has already begun. As of now, the Covovax Bridge is being studied in India. If Novavax gets approval for trials abroad, it is expected that SII will also receive approval here soon. It is expected to reach the market within two to three months. In December, 20 crores doses will be produced.

nasal vaccine

Coffee vaccine maker Bharat Biotech is preparing a nasal vaccine. This vaccine enters the body through the nose. The first trial of the vaccine is underway. It replaces the nasal vaccine (BBV154). It is very useful in preparing the antibody.

HGC019

Pune-based Geneva Biopharmaceutical Company has developed India’s first mRNA Covid-19 vaccine, called HGC019. A clinical trial of the vaccine began last month.

Leave a Reply

Your email address will not be published. Required fields are marked *